Literature DB >> 12386820

High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice.

Simonetta Pazzaglia1, Mariateresa Mancuso, Michael J Atkinson, Mirella Tanori, Simonetta Rebessi, Vincenzo Di Majo, Vincenzo Covelli, Heidi Hahn, Anna Saran.   

Abstract

Individuals affected with the Gorlin syndrome inherit a germ-line mutation of the patched (Ptc1) developmental gene and, analogously to Ptc1 heterozygous mice, show an increased susceptibility to spontaneous tumor development. Human and mouse Ptc1 heterozygotes (Ptc1(+/-)) are also hypersensitive to ionizing radiation (IR)-induced tumorigenesis in terms of basal cell carcinoma (BCC) induction. We have analysed the involvement of Ptc1 in the tumorigenic response to a single dose of 3 Gy X-rays in neonatal and adult Ptc1 heterozygous and wild type mice. We report that irradiation dramatically increased the incidence of medulloblastoma development (51%) over the spontaneous rate (7%) in neonatal but not adult Ptc1 heterozygotes, indicating that medulloblastoma induction by IR is subjected to temporal restriction. Analysis of Ptc1 allele status in the tumors revealed loss of the wild type allele in 17 of 18 medulloblastomas from irradiated mice and in two of three spontaneous medulloblastomas. To our knowledge, irradiated newborn Ptc1(+/-) heterozygous mice constitute the first mouse model of IR-induced medulloblastoma tumorigenesis, providing a useful tool to elucidate the molecular basis of medulloblastoma development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12386820     DOI: 10.1038/sj.onc.1205973

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

2.  Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.

Authors:  Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

3.  Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation.

Authors:  Jennifer Pogoriler; Kathleen Millen; Manuel Utset; Wei Du
Journal:  Development       Date:  2006-08-30       Impact factor: 6.868

4.  Pathways to chromothripsis.

Authors:  Robert Ivkov; Fred Bunz
Journal:  Cell Cycle       Date:  2015-07-15       Impact factor: 4.534

Review 5.  The Hedgehog's tale: developing strategies for targeting cancer.

Authors:  Jessica M Y Ng; Tom Curran
Journal:  Nat Rev Cancer       Date:  2011-05-26       Impact factor: 60.716

6.  Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma.

Authors:  Olivier Ayrault; Frederique Zindy; Jerold Rehg; Charles J Sherr; Martine F Roussel
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.

Authors:  Dolores Hambardzumyan; Oren J Becher; Marc K Rosenblum; Pier Paolo Pandolfi; Katia Manova-Todorova; Eric C Holland
Journal:  Genes Dev       Date:  2008-02-15       Impact factor: 11.361

8.  Developmental and oncogenic effects of insulin-like growth factor-I in Ptc1+/- mouse cerebellum.

Authors:  Mirella Tanori; Melissa Santone; Mariateresa Mancuso; Emanuela Pasquali; Simona Leonardi; Vincenzo Di Majo; Simonetta Rebessi; Anna Saran; Simonetta Pazzaglia
Journal:  Mol Cancer       Date:  2010-03-09       Impact factor: 27.401

9.  Tumor suppressor gene co-operativity in compound Patched1 and suppressor of fused heterozygous mutant mice.

Authors:  Jessica Svärd; Björn Rozell; Rune Toftgård; Stephan Teglund
Journal:  Mol Carcinog       Date:  2009-05       Impact factor: 4.784

Review 10.  Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Authors:  Jason T Huse; Eric C Holland
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.